Evidence map›Paper›PMID 41141218›Full record

ReviewBreast cancer (Dove Medical Press)2025

Exploring AI Approaches for Breast Cancer Detection and Diagnosis: A Review Article.

Akbar Ali, Mansoor Alghamdi, Shahira Sofea Marzuki, Tengku Ahmad Damitri Al Astani Tengku Din, Muhamad Syahmi Yamin, Malek Alrashidi, Ibrahim S Alkhazi, Naveed Ahmed

Abstract readReview
In one paragraph

Review in Breast cancer (Dove Medical Press), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Akbar AliDepartment of Chemical Pathology, School of Medical Science, Health Campus, Universiti Sains Malaysia 16150 Kubang Kerian, Kelantan, Malaysia.
Mansoor AlghamdiDepartment of Computer Science, Applied College, University of Tabuk, Tabuk, 71491, Saudi Arabia.
Shahira Sofea MarzukiDepartment of Chemical Pathology, School of Medical Science, Health Campus, Universiti Sains Malaysia 16150 Kubang Kerian, Kelantan, Malaysia.
Tengku Ahmad Damitri Al Astani Tengku DinDepartment of Chemical Pathology, School of Medical Science, Health Campus, Universiti Sains Malaysia 16150 Kubang Kerian, Kelantan, Malaysia.
Muhamad Syahmi YaminDepartment of Chemical Pathology, School of Medical Science, Health Campus, Universiti Sains Malaysia 16150 Kubang Kerian, Kelantan, Malaysia.ORCID 0009-0002-9108-9727
Malek AlrashidiDepartment of Computer Science, Applied College, University of Tabuk, Tabuk, 71491, Saudi Arabia.ORCID 0000-0001-8460-9240
Ibrahim S AlkhaziDepartment of Computer Science, College of Computers and Information Technology, University of Tabuk, Tabuk, 71491, Saudi Arabia.
Naveed AhmedDepartment of Assistance Medical Sciences, Applied College, University of Tabuk, Tabuk, 71491, Saudi Arabia.ORCID 0000-0003-1504-1705

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Artificial intelligence (AI), particularly deep learning, is reshaping breast cancer diagnostics in the radiology and pathology fields. This review synthesizes recent advances in mammography, digital breast tomosynthesis (DBT), ultrasound, MRI, and whole-slide imaging, with an emphasis on convolutional neural networks (CNNs), Vision Transformers (ViTs), and generative adversarial networks (GANs). When embedded within established screening and diagnostic workflows, AI systems can enhance lesion detection and triage, as well as reduce interpretive variability. However, performance and generalizability depend on dataset quality, population and vendor heterogeneity, acquisition protocols, and calibrated probability outputs; diminished performance on external datasets and miscalibration remain recurrent risks that require explicit mitigation during development and deployment of these models. Beyond detection and classification, segmentation and risk prediction models increasingly integrate imaging with clinicopathological and, where available, genomic variables to enable individualized risk stratification and follow-up planning. Data generation strategies, including GAN-based augmentation, can partially address data scarcity and class imbalance but require rigorous quality control and bias monitoring. Persistent barriers to clinical adoption include uneven external validation, domain shifts across institutions, variability in reporting standards, limited interpretability, and ethical, privacy, and regulatory constraints. Overall, AI should augment, rather than replace, the role of clinicians. Priorities for responsible integration include multi-site prospective evaluations, transparent and standardized reporting, bias mitigation, robust calibration, and lifecycle monitoring to ensure sustained safety and equity.

Indexed as

breast cancerCNNsdeep learningdigital pathologyexternal validationGANsmammography/DBTrisk predictionViTs

Identifiers

PMID41141218
PMCPMC12553387

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.